Dr. Ravindra Pandey Ravindra Pandey, PhD

Ravindra Pandey

PhD

Special Interests:

Photosensitizers for Photodynamic Therapy Molecular Modeling-Based Target-Specific Photosensitizers Bi-Functional Tumor-Imaging (MRI, PET and Fluorescence) and Therapeutic Agents PDT and Nanotechnology Models for Photosynthetic Reaction Centers

About Ravindra Pandey

Biography:

After completing a PhD from the University of Rajasthan, Jaipur, India in Medicinal Chemistry, Dr. Pandey worked as a postdoctoral fellow and research associate in the laboratories of Professor Kevin M. Smith (University of California, Davis, 1980-1983 and 1984-1986) and the late Professor A. H. Jackson (University College Cardiff, Wales, 1983-1984) on the chemistry and biochemistry aspects of porphyrin-based compounds. He joined Oncologic Foundation of Buffalo in 1986 and was involved in a photodynamic therapy project related to Photofrin® research funded by Johnson & Johnson. In 1990 he left the Foundation and joined the Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center, Buffalo, where he is currently associated as Distinguished Professor and Director of Pharmaceutical Chemistry, Department of Cell Stress Biology. He also has an appointment as Professor with the Institute of Lasers, Photonics and Biophotonics, SUNY at Buffalo.

Dr. Pandey is a member of the editorial boards of the Journal of Porphyrins and Phthalocyanines, Current Organic Chemistry and Current Organic Synthesis. He is a founding member of the International Society of Porphyrins and Phthalocyanines. He has organized several national and international scientific symposiums and has delivered a large number of plenary and invited lectures all over the world on PDT and tumor imaging. He has received several awards including the Inventor of the Year Award (Niagara Frontier), the Rajiv Gandhi Award of Excellence, and “Who's Who in Science.” He has been a reviewer of research grants for various federal agencies (US, UK, Canada, Singapore, France) and private foundations. He has 30 patents to his credit and published over 200 research papers in various reputed international journals, as well as several review articles and book chapters. His research is well funded by national funding agencies and private organizations.

Dr. Pandey is also the founder of Photolitec, LLC, a biotech company. The goal of this organization is to develop cancer imaging and therapeutic agents and also to start clinical trials in developing countries.

Positions

Roswell Park Comprehensive Cancer Center
  • Professor and Distinguished Member, Cellular Stress Biology
  • Director, Pharmaceutical Chemistry
State University of New York at Buffalo
  • Research Professor
  • Institute of Lasers, Photonics and Biophotonics

Background

Education and Training:

  • PhD - Medicinal Chemistry, University of Rajasthan, Jaipur, India

Fellowship:

  • 1984-1986 - Postdoctoral Fellow & Research Associate - University of California, Davis
  • 1983-1984 - Postdoctoral Fellow & Research Associate - University College Cardiff, Wales
  • 1980-1983 - Postdoctoral Fellow & Research Associate - University of California, Davis

Professional Memberships:

  • Founding Member, International Society of Porphyrins and Phthalocyanines

Professional Experience:

  • 1990-Present - Photodynamic Therapy Center, Roswell Park Comprehensive Cancer Center
  • 1986-1990 - Oncologic Foundation of Buffalo

Honors & Awards:

  • Inventor of the Year Award, Niagara Frontier
  • Rajiv Gandhi Award of Excellence

Research

Research Overview:

Dr. Pandey has been working on the synthesis of porphyrin-based compounds for the last 28 years and investigating their application for use in PDT for the last 23 years. His group was responsible for characterizing the active components of Photofrin®, which also played an important role in its worldwide approval for use in photodynamic therapy. His current research interests are focused on developing “multifunctional agents,” nanoparticles for tumor imaging (PET, MRI, fluorescence)/PDT to develop models for photosynthetic reaction centers and to explore the chemistry of porphyrin-based compounds related to chlorins and bacteriochlorins. Most of the photosensitizers and tumor imaging agents developed in his group are derived from naturally occurring chlorophyll-a and bacteriochlorophyll-a. One of his compounds (HPPH) is currently in Phase II human clinical trials and several more are in various stages of preclinical and toxicological studies.


Publications

Full Publications list on PubMed
  • Gupta A, Pandey RK, Supramolecular approach for tumor imaging and photodynamic therapy in Suptrmaolecular Systems in Biomedical Fields (Ed: Schneider HJ), RSC Publishing, Cambridge, UK, 2013.
  • Gupta A, Wang S, Pera P, Rao KVR, Patel N, Ohulchanskyy TY, Missert J, Morgan J, Koo-Lee Y-E, Kopelman R, Pandey RK. Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles. Nanomedicine: nanotechnology, biology, and medicine 2012; 8(6):941-950
  • Chen Y, Sajjad M, Wang Y, Batt C, Nabi HA, Pandey RK. TSPO 18 kDa (PBR) targeted photosensitizers for cancer imaging (PET) and PDT. ACS medicinal chemistry letters 2011; 2(2):136-141
  • Ethirajan M, Joshi P, William WH, Ohkubo K, Fukuzumi S, Pandey RK. Remarkable Regioselective Position-10 Bromination of Bacteriopyropheophorbide-a and Ring-B Reduced Pyropheophorbide-a. Organic letters 2011; 13(8):1956-1959
  • Gupta A, Prasad PN, Morgan J, Roy I, Ohulchanskyy T, Rao KVR, Missert J, Ethirajan M, Goswami LN, Pandey RK. Organically modified silica nanoparticles as drug delivery vehicles in photodynamic therapy. Journal of porphyrins and phthalocyanines 2011; 15(5-6):401-411
  • Srivatsan A, Morgan J, Missert J, Shibata M, Liu T-H, Zheng X, Dubey S, Pandey SK, Ethirajan M, Pandey RK. Conjugation of cRGD peptide to chlorophyll a based photosensitizer (HPPH) alters its pharmacokinetics with enhanced tumor-imaging and photosensitizing (PDT) efficacy. Molecular pharmaceutics 2011; 8(4):1186-1197
  • Wang S, Morgan J, Pera P, Goswami LN, Gupta A, Ethirajan M, Kopelman R, Lee Y-EK, Hah HJ, Kim G, Fan W, Pandey RK. Novel methods to incorporate photosensitizers into nanocarriers for cancer treatment by photodynamic therapy. Lasers in surgery and medicine 2011; 43(7):686-695
  • Srivatsan A, Wang Y-F, Joshi P, Sajjad M, Chen Y-H, Liu C, Thankppan K, Missert JR, Tracy E, Morgan J, Rigual N, Baumann H, Pandey RK. In vitro cellular uptake and dimerization of signal transducer and activator of transcription-3 (STAT3) identify the photosensitizing and imaging-potential of isomeric photosensitizers derived from chlorophyll-a and bacteriochlorophyll-a. Journal of medicinal chemistry 2011; 54(19):6859-6873
  • Gil M, Bieniasz M, Seshadri M, Fisher D, Ciesielski MJ, Chen Y, Pandey RK, Kozbor D. Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. British journal of cancer 2011; 105(10):1512-1521
  • Joshi P, Ethirajan M, Goswami LN, Srivatsan A, Missert JR, Pandey RK.Synthesis, spectroscopic, and in vitro photosensitizing efficacy of ketobacteriochlorins derived from ring-B and ring-D reduced chlorins via pinacol-pinacolone rearrangement. Journal of organic chemistry 2011; 76(21):8629-8640
  • Saenz C, Ethirajan M, Iacobucci G, Pandey A, Missert JR, Dobhal MP, Pandey RK. Indium as a central metal enhances the photosensitizing efficacy of benzoporphyrin derivatives. Journal of porphyrins and phthalocyanines 2011; 15(11-12):1310-1316
  • Tracy EC, Bowman MJ, Pandey RK, Henderson BW, Baumann H. Cell-type selective phototoxicity achieved with chlorophyll-a derived photosensitizers in a co-culture system of primary human tumor and normal lung cells. Photochemistry and photobiology 2011; 87(6):1405-1418
  • Williams MP, Ethirajan M, Ohkubo K, Chen P, Pera P, Morgan J, White WH 3rd, Shibata M, Fukuzumi S, Kadish KM, Pandey RK. Synthesis, photophysical, electrochemical, tumor-imaging, and phototherapeutic properties of purpurinimide-N-substituted cyanine dyes joined with variable lengths of linkers. Bioconjugate chemistry 2011; 22(11):2283-2295
  • Ethirajan M, Chen Y, Joshi P, Pandey RK. The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chemical Society reviews 2011; 40(1):340-362
  • Spernyak JA, Mazurchuk R, Batt C, Missert JR, Turowski S, Chen Y, Goswami L, Patel NJ, Ethirajan M, White WH, Pandey RK. Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy. Bioconjugate chemistry 2010; 21(5):828-835
  • Pandey RK. Nanoplatform for tumor imaging and therapy. Medicinal chemistry research 2010; 19(Suppl. 1):S31
  • Pandey RK, James NS, Chen Y, Missert J, Sajjad M. Bifunctional agents for imaging and therapy. Methods in molecular biology (Clifton, N.J.) 2010; 635:223-259
  • Morgan J, Jackson JD, Zheng X, Pandey SK, Pandey RK. Substrate Affinity of Photosensitizers Derived from Chlorophyll-a: The ABCG2 Transporter Affects the Phototoxic Response of Side Population Stem Cell-like Cancer Cells to Photodynamic Therapy. Molecular pharmaceutics 2010; 7(5):1789-1804
  • Goswami LN, White WH, Spernyak JA, Ethirajan M, Chen Y, Missert JR, Morgan J, Mazurchuk R, Pandey RK. Synthesis of Tumor-avid Photosensitizer-Gd(III)DTPA conjugates: impact of the number of gadolinium units in T1/T2 relaxivity, intracellular localization, and photosensitizing efficacy. Bioconjugate chemistry 2010; 21(5):816-827
  • Ethirajan M, Williams M, Angelino N, Missert JR, Pandey RK. Development of novel bifunctional agents with and without tumor imaging ability. Proceedings of SPIE : Biomedical Optics and Medical Imaging 2009; 7380:73806K
  • Gupta A, Rao KVR, Pera P, Wang SJ, Missert JR, Ohulchanskyy T, Roy I, Morgan J, Prasad PN, Kopelman R, Pandey RK. Multifunctional ORMOSIL and PAA nanoparticles. Proceedings of SPIE : Biomedical Optics and Medical Imaging 2009; 7380:73805H
  • Muffoletto D, Gupta A, Xu Z, Mahrer C, Bauer G, Galas S, Pandey RK, Sunar U. Imaging of a targeted PDT drug with fluorescence tomography. Proceedings of SPIE : Biomedical Optics and Medical Imaging 2009; 7164:716409
  • Srivatsan A, Rao KVR, Chen Y, Wang Y, Batt C, Morgan J, Sen A, Repasky E,Pandey RK. Effect of hyperthermia on PDT and imaging. Proceedings of SPIE : Biomedical Optics and Medical Imaging 2009; 7380:73805V
  • Goswami LN, Ethirajan M, Dobhal MP, Zhang M, Missert JR, Shibata M, Kadish KM, Pandey RK. Remarkable features of the McMurry reaction conditions in dimerization of formyl- and 2-formylvinylpurpurinimides. Electrochemistry of monomeric Ni(II) purpurinimide and the corresponding dyads. Journal of organic chemistry 2009; 74(2):568-579
  • Kim S, Ohulchanskyy TY, Bharali D, Chen Y, Pandey RK, Prasad PN.Organically modified silica nanoparticles with intraparticle heavy-atom effect on the encapsulated photosensitizer for enhanced efficacy of photodynamic therapy. Journal of physical chemistry. C, Nanomaterials and interfaces 2009;113(29):12641-12644
  • Pandey SK, Oseroff AR, Nabi HA, Yao R, Batt C, Missert JR, Pandey A, Chen Y, Sajjad M, Pandey RK. Compared to purpurinimides, the pyropheophorbide containing an iodobenzyl group showed enhanced PDT efficacy and tumor imaging (124I-PET) ability. Bioconjugate chemistry 2009; 20(2):274-282
  • Pandey SK, Oseroff AR, Nabi HA, Batt C, Missert JR, Yao R, Zheng X, Chen Y, Sajjad M, Pandey RK. Comparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I- labeled methyl- 3-(1'-iodobenzyloxyethyl)pyropheophorbide-a vs the corresponding glucose and galactose conjugates. Journal of medicinal chemistry 2009; 52(2):445-455
  • Zheng X, Henderson BW, Bellnier DA, Jackson J, Batt C, Missert JR, Baumann H, Tracy E, Chen Y, Pandey SK, Morgan J, Pandey RK. Conjugation of 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. Journal of medicinal chemistry 2009; 52(14):4306-4318
  • Fukuzumi S, Ohkubo K, Zheng X, Chen Y, Pandey RK, Zhan R, Kadish KM.Metal bacteriochlorins which act as dual singlet oxygen and superoxide generators. Journal of physical chemistry. B 2008; 112(9):2738-2746
  • Liu C, Ohkubo K, Kadish KM, Zhang M, Sukumaran DK, Balasubramanian S,Pandey RK, Missert JR, Ethirajan M, Dobhal MP, Fukuzumi S. Highly selective synthesis of the ring-B reduced chlorins by ferric chloride-mediated oxidation of bacteriochlorins: effects of the fused imide vs isocyclic ring on photophysical and electrochemical properties. Journal of the American Chemical Society 2008; 130(43):14311-14323
  • Pandey RK, Zheng X, Dobhal MP, Smith KM. Formation of chlorins and meso-substituted porphyrins through intramolecular nitrogen-carbon migration of N-substituted porphyrins. Journal of porphyrins and phthalocyanines 2008; 12(2):131-141
  • Zheng X, Pandey RK. Porphyrin-carbohydrate conjugates: impact of carbohydrate moieties in photodynamic therapy (PDT). Anti-cancer agents in medicinal chemistry 2008; 8(3):241-268
  • Baba K, Pudavar HE, Roy I, Ohulchanskyy TY, Chen Y, Pandey RK, Prasad PN. New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug. Molecular pharmaceutics 2007; 4(2):289-297
  • Chen Y, Potter WR, Missert JR, Morgan J, Pandey RK. Comparative in vitro and in vivo studies on long-wavelength photosensitizers derived from bacteriopurpurinimide and Bacteriochlorin p6: fused imide ring enhances the in vivo PDT efficacy. Bioconjugate chemistry 2007; 18(5):1460-1473
  • Chen Y, Shibata M, Rajeswaran M, Srikrishnan T, Dugar S, Pandey RK. Utility of Japp-Klingemann reaction for the preparation of 5-carboxy-6-chloroindole via Fischer indole protocol. Tetrahedron letters 2007; 48(13):2353-2356
  • Gryshuk A, Oseroff A, Prasad PN, Potter W, Ohulchanskyy T, Missert JR, Pandey S, Goswami LN, Chen Y, Pandey RK. Structure-activity relationship among purpurinimides and bacteriopurpurinimides: trifluoromethyl substituent enhanced the photosensitizing efficacy. Journal of medicinal chemistry 2007; 50(8):1754-1767
  • Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. Journal of the American Chemical Society 2007; 129(9):2669-2675
  • Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, Pandey RK, Oseroff AR, Prasad PN. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano letters 2007; 7(9):2835-2842
  • Pandey SK, Dougherty TJ, Henderson BW, Oseroff AR, Bellnier DA, Shibata M, Liu TH, Missert JR, Morgan J, Zheng X, Pandey RK. Purpurinimide carbohydrate conjugates: effect of the position of the carbohydrate moiety in photosensitizing efficacy. Molecular pharmaceutics 2007; 4(3):448-464
  • Ramaprasad S, Ripp E, Missert J, Pandey RK. In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model. Current drug discovery technologies 2007; 4(2):126-132
  • Chen Y, Oseroff A, Fenstermaker R, Kadish KM, Fukuzumi S, Erin T, Baumann H, Ciesielski M, Pandey SK, Liu W, Wenbo E, Zhang M, Ohkubo K, Pandey RK.Photophysical, electrochemical characteristics and cross-linking of STAT-3 protein by an efficient bifunctional agent for fluorescence image-guided photodynamic therapy. Photochemical and photobiological sciences 2007; 6(12):1257-1267

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment